当院のマイコプラズマジェニタリウム感染症の臨床的検討Clinical investigation of Mycoplasma genitalium infections at our clinic
医療法人奏仁会大阪梅田紳士クリニックOsaka-umeda Shinshi Clinic
2023年1月から12月に当院を受診した尿道炎症状を有する患者304例を対象に、Mycoplasma genitalium(MG)陽性率および臨床的特徴を分析した。MG陽性率は20.1%(61/304例)で、初回治療後の治癒確認受診率は49.2%(30/61例)、そのうち陰性化が確認できたのは56.7%(17/30例)にとどまった。さらに、淋菌・クラミジアとの重複感染は18.0%に認めたが、初診時にNG/CT PCRのみを提出し後日TV/MG PCRを追加した場合は、NG/CT PCRとTV/MG PCRを同時提出した場合に比し、重複感染の検出率が有意に低いことが示された。尿道炎診療において、淋菌・クラミジアとMGの重複感染の見逃しを防ぐためにも、初診時からの適切なスクリーニングが重要であり、加えてMGに対する標準化された治療指針の整備が求められる。
We analyzed the Mycoplasma genitalium (MG) positivity rate and clinical characteristics in 304 patients presenting with symptoms of urethritis who visited our clinic from January to December 2023. The MG positivity rate was 20.1% (61/304 cases). Among MG-positive patients, the rate of follow-up visits for post-treatment confirmation was 49.2% (30/61 cases); of these patients, MG eradication was confirmed in only 56.7% (17/30 cases). Coinfection with Neisseria gonorrhoeae and/or Chlamydia trachomatis was observed in 18.0% of the MG-positive cases. However, patients who initially underwent only NG/CT PCR testing and subsequently added TV/MG PCR demonstrated significantly lower detection rate of coinfections than those who simultaneously received both tests at the initial visit. These findings suggest that appropriate screening at the initial consultation, including testing for MG, is crucial for preventing missed diagnoses of MG and its coinfections. Furthermore, the development of standardized treatment guidelines for MG is warranted.
Key words: Mycoplasma genitalium; urethritis; screening timing; treatment outcome; coinfection
© 2026 一般社団法人日本性感染症学会© 2026 Japanese Society for Sexually Transmitted Infections
This page was created on 2025-12-22T11:09:53.726+09:00
This page was last modified on 2026-03-17T11:14:57.000+09:00
このサイトは(株)国際文献社によって運用されています。